COPENHAGEN, Denmark and SHANGHAI, Aug. 20, 2024 /PRNewswire/ — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC)…